undamentalytics Newsletter
Sign in

Annovis Bio, Inc. balance sheet

At the end of fiscal 2025, Annovis Bio, Inc. had total assets of $21.1m, total liabilities of $4.2m and shareholders' equity of $16.9m. It held $19.5m in cash against $0 of debt: net cash of $19.5m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents0846286112019
Total current assets18463610———
Total assets18463610142122
Accounts payable10141233
Total current liabilities21284446
Long-term debt0———————
Total debt0—000000
Total liabilities3128185426
Shareholders' equity−984428−8917−4
Non-controlling interests and other (assets − liabilities − equity)7———————
Net debt (negative = net cash)0−8−46−28−6−11−20−19
Shares outstanding—7m8m8m11m14m——

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Annovis Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Annovis Bio, Inc.